ReviewInternational journal of technology assessment in health care2023
A review of HTA guidelines on societal and novel value elements.
Review in International journal of technology assessment in health care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology and burden of respiratory syncytial virus in Italian adults: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Using a lottery to resolve indeterminacy when allocating resources for drugs for rare diseases.Journal of medical ethics · 2026Article
- What is the Value of Developing an HTA Process?PharmacoEconomics · 2026Review
- Ethical Considerations in Health Technology Assessment for Precision Medicine: A Delphi Study in a Greek Setting.Journal of personalized medicine · 2026Article
- Adopting a Societal Perspective in Health-Economic Evaluation: Analysis of Nine HTA Methodological Guidelines on How to Integrate Societal Costs.Journal of market access & health policy · 2026Article
- Measuring and valuing spillover effects in caregivers and families: A scoping review.PloS one · 2026Article
- Scoping Review of Productivity-Adjusted Life Years (PALYs): Methods, Applications and Policy Implications.PharmacoEconomics · 2025Article
- Stakeholder survey about broad elements of value in health technology assessment in Australia: industry and academia more similar than different.International journal of technology assessment in health care · 2025Article
- Access in all areas? A roundup of developments in market access and health technology assessment: part 6.Journal of comparative effectiveness research · 2025Article
- The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis.PharmacoEconomics · 2025Article
- Defining the value proposition in diagnostic technology: challenges and opportunities for its understanding and development - a review with a multiperspective reflective analysis.Frontiers in medicine · 2025Review
- Article
- Val (EU) xit: do we need an international ISPOR value flower?Journal of comparative effectiveness research · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- The economic and fiscal impact of incremental use of cell-based quadrivalent influenza vaccine for the prevention of seasonal influenza among healthcare workers in Italy.Health research policy and systems · 2024Article
- Is the price right? Paying for value today to get more value tomorrow.BMC medicine · 2024Article
- The value and impact of health technology assessment: discussions and recommendations from the 2023 Health Technology Assessment International Global Policy Forum.International journal of technology assessment in health care · 2023Article
- Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies.PharmacoEconomics · 2023Article
- Access in all areas? A round up of developments in market access and health technology assessment: part 1.Journal of comparative effectiveness research · 2023Article
- Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesHealth technology assessment (HTA) organizations vary in terms of how they conduct assessments. We assess whether and to what extent HTA bodies have adopted societal and novel elements of value in their economic evaluations.
methodsAfter categorizing "societal" and "novel" elements of value, we reviewed fifty-three HTA guidelines. We collected data on whether each guideline mentioned each societal or novel element of value, and if so, whether the guideline recommended the element's inclusion in the base case, sensitivity analysis, or qualitative discussion in the HTA.
resultsThe HTA guidelines mention on average 5.9 of the twenty-one societal and novel value elements we identified (range 0-16), including 2.3 of the ten societal elements and 3.3 of the eleven novel value elements. Only four value elements (productivity, family spillover, equity, and transportation) appear in over half of the HTA guidelines, whereas thirteen value elements are mentioned in fewer than one-sixth of the guidelines, and two elements receive no mention. Most guidelines do not recommend value element inclusion in the base case, sensitivity analysis, or qualitative discussion in the HTA.
conclusionsIdeally, more HTA organizations will adopt guidelines for measuring societal and novel value elements, including analytic considerations. Importantly, simply recommending in guidelines that HTA bodies consider novel elements may not lead to their incorporation into assessments or ultimate decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.